WO1998046576A2 - Promedicaments haloalcoxycarbonyles - Google Patents

Promedicaments haloalcoxycarbonyles Download PDF

Info

Publication number
WO1998046576A2
WO1998046576A2 PCT/US1998/007092 US9807092W WO9846576A2 WO 1998046576 A2 WO1998046576 A2 WO 1998046576A2 US 9807092 W US9807092 W US 9807092W WO 9846576 A2 WO9846576 A2 WO 9846576A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
phenyl
aminoiminomethyl
substituted
Prior art date
Application number
PCT/US1998/007092
Other languages
English (en)
Other versions
WO1998046576A3 (fr
Inventor
Brent Blackburn
Alan G. Olivero
Kirk Robarge
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to DE69830577T priority Critical patent/DE69830577T2/de
Priority to EP98913417A priority patent/EP0975608B1/fr
Priority to AU67972/98A priority patent/AU6797298A/en
Priority to AT98913417T priority patent/ATE297904T1/de
Priority to JP54404298A priority patent/JP2001521522A/ja
Publication of WO1998046576A2 publication Critical patent/WO1998046576A2/fr
Publication of WO1998046576A3 publication Critical patent/WO1998046576A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • This invention relates to novel halo-alkoxycarbonyl derivatives as bioconvertable prodrug moieties for pharmaceutical agents containing a polar or basic functionality.
  • the invention also relates to novel pharmaceutical compositions containing a prodrug comprising the novel prodrug moieties as a component, as well as to processes for producing the prodrugs.
  • the invention further relates to methods for using the novel pharmaceutical compositions described herein.
  • Enzyme Inhibition 9:73-86 possess a polar or basic functional group which is integrally responsible for the desired biological activity.
  • structurally related receptors such as integrins recognize the amino acid sequence Arg-Gly-Asp known to be expressed in the extracellular surface glycoprotein GPIIb/IIIa of platelets, endothelial cells, leukocytes, lymphocytes, monocytes and granulocytes.
  • Pharmaceutical agents having the amino acid sequence Arg-Gly-Asp, chemically modified derivatives thereof or non-peptidal analogs, having a polar or basic functionality compete with intracellular adhesive factors to limit or prevent a key step in the aggregatory cascade.
  • this polar functional group is a nitrogen atom of, for example, a guanidine, alkyl-amidine or aryl-amidine group.
  • these functionalities being good peptidomimetics for the guanidine group of arginine, an important amino acid residue found in many of the natural ligands and substrates of the indicated proteins and enzymes.
  • these functionalities are highly basic (for example, pK a of the conjugate acid ⁇ 11), they remain protonated at physiologically relevant pH's. The ionic nature of such protonated species hinders their permeability across lipophilic membranes which can reduce bioavailability when the pharmaceutical agent is administered orally.
  • the derivatization In order to circumvent such a problem, it is often advantageous to perform a derivatization or chemical modification of the polar functionality such that the pharmaceutical agent becomes neutrally charged and more lipophilic thereby facilitating absorption of the drug.
  • the derivatization must be bioconvertable at the target site or sites of desired pharmacological activity and cleaved under normal physiological conditions to yield the biologically active drug.
  • prodrug has been used to denote such a chemically modified intermediate.
  • alkoxycarbonyl (carbamoyl) and acyloxymethyl carbamate groups have been investigated as prodrug moieties capable of producing a bioconvertable prodrug of amine and amidine nitrogens (for example, Saulnier, et al. (1994) Bioorg. Med. Chem. Letts. 4(16): 1985-1990).
  • Lower alkoxycarbonyl groups such as methoxycarbonyl and ethoxycarbonyl, optionally substituted phenoxycarbonyl groups, groups such as benzyloxycarbonyl and p-methoxybenzyloxycarbonyl and amide oximes have been described as prodrug moieties for these functional groups (for example, European Patent Application No. 0743320).
  • carbamoyl group has many of the desired characteristics to be utilized as a prodrug moiety, it suffers from the disadvantage that the group is not readily bioconvertable.
  • Alkoxycarbonylamines cleave too slowly in plasma and upon systemic circulation to the respective amine to be of prlactical importance. This is partly due to the fact that mammals possess no carbamoyl specific hydrolases. Cholinesterases have been shown to slowly hydrolyze some carbamates, however the cleavage is slow and the cleaving enzyme is reversibly inhibited by the cleavage resulting in a further reduction in the rate of hydrolysis (Alexander et al., (1988) J. Med. Chem. 31 :318-322).
  • the present invention provides modified alkoxycarbonyl groups as bioconvertable prodrug moieties for pharmaceutical agents, drugs or medicaments having a polar or basic functional group. It is a feature of the present invention that when administered to animals including humans the pharmaceutical compositions comprising the novel prodrugs are more bioavailable following non-systemic administration than the parent pharmaceutical agents or drugs from which they are derived.
  • the novel prodrugs which comprise the prodrug moiety of the present invention may be used wherever the parent drug or pharmaceutical agent is used and advantageously provide increased biomembrane transport and improved bioavailability from the gastrointestinal tract, rectum, skin and the eyes.
  • the prodrugs of the invention can be incorporated into unit dosage forms such as tablets and capsules for oral delivery, as well as into suspensions, ointments and the like, depending on the particular drug or medicament and its target area.
  • the present invention provides such prodrug forms of pharmaceutical agents which following administration cleave in a therapeutically useful time frame and in such a manner as to enable the original parent composition to be released at its therapeutic site or sites of activity and to further permit the cleaved prodrug moiety to be metabolized in a nontoxic fashion.
  • the pharmaceutical composition comprising the prodrug moiety of the present invention can be described by the following formula:
  • [(H)o -2 (X)!- 3 ] is selected from the group consisting of X 3 , HX 2 , and H 2 X and X is a halogen
  • R and R are the same or different and are selected from the group consisting of H, Cj-C 4 alkyl, C 1 -C 4 alkoxy, cyano and halo(F, Cl,
  • Q is a basic N-containing functionality selected from the group consisting of an amino, amidino, aminoalkyleneamino, iminoalkyleneamino, and guanidino group.
  • the prodrug moiety -COO[C(R R )] z C[(H)o -2 (X) 1-3 ] is linked to the N containing functionality via an N atom.
  • halo-alkoxycarbonyl moieties for example, 2,2,2-tri-halo-ethoxycarbonyl moities are provided as bioconvertable prodrug moieties for polar or basic functionalities in pharmaceutical agents, drugs or medicaments.
  • Preferred polar or basic functionalities represented by Q or B-Q herein, are N-containing functionalities having a pK a of the conjugate acid sufficiently high that the N-containing group is at least 10% positively charged at physiological pH.
  • Exemplary N-containing functional groups, Q are primary and secondary amino, amidino, aminoalkyleneamino, iminoalkyleneamino, and guanidino groups.
  • guanidino and amidino groups and B-Q groups such as the alkyl-, alkenyl, alkynyl, substituted or unsubstituted aryl, arylalkyl, heterocyclic or heteroaromatic such as substituted or unsubstituted phenyl-, napthyl-, and pyridyl-amidino groups.
  • the prodrug moiety is a 2,2,2,-trichloroethoxycarbonyl group.
  • the prodrug moiety can be represented by the following structure:
  • the prodrug moiety can be represented by P or P' and the pharmaceutical agent can be represented by AG-Q with Q representing an N-containing functionality of the parent agent.
  • Q is an amidino group and the prodrug of the present invention is represented by the following two tautomeric structures:
  • AG represents a parent pharmaceutical agent substructure and wherein P and P' are the same or different and are independently selected from H or a 2,2,2,-tri-halo-ethoxycarbonyl moiety, at least one of P or P' being a 2,2,2-tri-halo-ethoxycarbonyl moiety where the ethoxycarbonyl group is linked to the N- containing functionality via the carbonyl group.
  • the ethoxy group is -OCH 2 CX 3 , -0CHR 2 CX 3 , or -OCR 2 R 3 CX 3 , R 2 and R 3 being defined herein, and preferably being H.
  • Q is B-Q and the pharmaceutical agent can be represented by AG-B-Q wherein B is an substituted or unsubstituted alkyl, alkenyl or alkynyl, a substituted or unsubstituted aryl, arylalkyl, heterocyclic, or heteroaromatic.
  • B is an unsubstituted or substituted phenyl, napthyl or pyridyl.
  • Q is an amidino group and the prodrug is represented by the following two tautomeric structures:
  • AG represents a parent pharmaceutical agent substructure and wherein P and P' are the same or different and are independently selected from H or a 2,2,2-trichloroethoxycarbonyl moiety, at least one of P or P' being a 2,2,2-trichloroethoxycarbonyl moiety where the ethoxycarbonyl group is linked to the N- containing functionality via the carbonyl group.
  • B is preferably an unsubstituted or substituted aryl or arylalkyl such as phenyl. napthyl or pyridyl.
  • the ethoxy group is - 0CH 2 CC1 3 , -0CHR 2 CC1 3 , or -0CR 2 R 3 CC1 3 , R 2 and R 3 being defined herein and preferably being H.
  • the invention further provides novel compositions comprising the prodrugs of the present invention as well as methods of making and employing the novel prodrugs.
  • the pharmaceutical compositions comprising the prodrugs of the present invention include all stereoisomers and pharmaceutically acceptable salts of the novel compositions.
  • Figure 1 A variety of alkoxycarbonylamidines were prepared including benzyloxy- butoxy, isobutoxy, (4-pyridyl)methoxy-, 1-morpholinoethoxy-, however no increases in oral bioavailability relative to the ethoxycarbonyl compounds were observed in any parent class. As part of a program to understand why these alkoxy carbonyl prodrugs were showing low oral availability, in vitro and in vivo studies were conducted to identify whether prodrug to parent conversion was limiting the oral activity.
  • Figure 2 is a graphic representation of the percent conversion of various prodrugs to bioactive parent compound in rat plasma after 30 minute incubation. The ability to cleave under physiological conditions was demonstrated for various alkoxycarbonyl derivatives of GPIIb/IIIa antagonists. Unlike simple alkoxycarbonylamidines such as the ethoxycarbonyl derivative (entry 1) the 2,2,2- trichloroethoxycarbonyl modified amidines (entry 5) cleave readily in rat plasma to yield the active metabolite.
  • Figure 3 Figure 3 graphically depicts the bioavailability (%F) upon intravenous administration of various prodrugs in rats at 2 mg/kg.
  • alkoxycarbonylamidine prodrugs Upon delivery of alkoxycarbonylamidine prodrugs by intravenous administration, simple alkylcarbamoyl amidines do not readily convert to the active metabolite whereas the 2,2,2-trichloroethoxycarbonyl derivatives cleaves to greater than 38%.
  • Figure 4 depicts graphically the conversion of various prodrugs to the active parent in dog hepatocytes at 37 C.
  • the 2,2,2-trichloroethoxycarbonylamidines effectively cleaves in dog hepatocytes to yield the bioactive parent compound.
  • Figure 5 Figure 5 graphically depicts bioavailability (%F) of compounds of the general formula I:
  • Figure 7 show the results of oral bioavailability assessed by dosing mice at 100 mg/kg orally and sacrificing the mice at either 1 or 3 hour timepoints. The mice were exsanguinated and ex vivo platelet aggregation measured by ID50.
  • compositions or parent compounds characteristically contain at least one polar or basic nitrogen- (N-) containing functionality. It is characteristic that the pharmaceutical agent comprising at least one N-containing functionality have a pK a of the conjugate acid sufficiently high so that the functionalities are at least 10% positively charged at physiological pH. Functionalities that are positively charged are associated with an H ion at physiological pH.
  • the pharmaceutical agent or parent drug is represented by the shorthand notation AG-Q or AG-B-Q.
  • AG is conveniently used in place of the parent drug "substructure" with Q, or B-Q representing the parent drug at least one polar or basic N-containing functionality as defined herein, B further defining the parent drug substructure.
  • the parent drug is an amidine containing GPIIb/IIIa antagonist such as those described in International Publication No. WO 93/08174 and U.S. Patent No. 5,565,449.
  • AG may contain a substituted or unsubstituted aryl or arylalkyl-amidino group represented by -B-Q.
  • the pharmaceutical agent is pharmaceutically active or "bioactive,” by virtue of possessing a biological activity such as inhibiting platelet aggregation in the absence of the prodrug moiety of the present invention.
  • a biological activity such as inhibiting platelet aggregation in the absence of the prodrug moiety of the present invention.
  • it is a characteristic of the pharmaceutical agent of the present invention that it contain at least one polar or basic N-containing functionality (Q) as herein defined.
  • Q polar or basic N-containing functionality
  • basic as used in the context of the present invention refers to a funtionality or moiety having a positive charge due to association with H ion at physiological pH.
  • polar refers to funtionalities or moieties not charged at physiological pH, but possess a dipole moment in an aqueous (non-lipid) environment.
  • Bioavailable as used herein means that at least some amount of the parent drug is present in the systemic circulation. Formal calculations of oral bioavailability are described in terms of an F value ("Fundamentals of Clinical Pharmacokinetics," John G. Wegner, Drug Intelligence Publications; Hamilton, Illinois 1975). F values are derived from the ratio of the concentration of the parent drug in the systemic circulation (e.g., plasma) following intravenous administration to the concentration of the parent drug in the systemic circulation after administration by a non-intravenous route (e.g., oral).
  • oral bioavailability within the scope of the present invention contemplates the ratio or F value of the amount of parent drug detectable in the plasma after oral administration compared to intravenous administration.
  • “Pharmaceutically acceptable salts” include both acid and base addition salts.
  • the term “prodrug” is used herein to refer to a derivative of a parent drug that has enhanced pharmaceutically desirable characteristics or properties (e.g. transport, bioavailablity, pharmacodynamics, etc.) and requires “bioconversion,” i.e., cleavage of the "prodrug moiety” either spontaneously or enzymatically, within the organism to release the active parent drug.
  • alkyl or the prefix “alk” mean a branched or unbranched, saturated aliphatic hydrocarbon radical, having the number of carbon atoms specified, or if no number is specified, having up to about 12 carbon atoms.
  • alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 2,2- dimethylbutyl, n-heptyl, 2-methylhexyl, and the like.
  • lower alkyl C1-C6 alkyl
  • alkyl of 1 to 6 carbon atoms are synonymous and used interchangeably.
  • a preferred "C ⁇ -C6 alkyl” group is ethyl.
  • Substituted alkyl groups include those that are substituted by one, two or three halogen, hydroxy, amino, carboxy, acyloxy (substituents such as formyloxy, acetoxy, proprionyloxy, butyryloxy, pentanoyloxy and the like,) carbamoyl, carbamoyloxy, cyano, morpholino, or methylsulfonylamino substituents and the like.
  • Examples of the above substituted alkyl groups include but are not limited to, hydroxyethyl, 2- mo ⁇ holinoethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-amino(iso-propyl), 2-carbamoyloxyethyl and the like.
  • alkenyl means a branched or unbranched hydrocarbon radical having the number of carbon atoms designated containing one or more carbon-carbon double bonds, each double bond being independently cis, trans, or a nongeometric isomer.
  • alkynyl means a branched or unbranched hydrocarbon radical having the number of carbon atoms designated containing one or more carbon-carbon triple bonds.
  • alkoxy or "Cj-Ci2 alkoxy” and the like are used interchangeably herein and denote groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups.
  • Substituted alkoxy groups include those that are substituted by one, two or three halogen, hydroxy, amino, carboxy, acyloxy (substituents such as formyloxy, acetoxy, proprionyloxy, butyryloxy, pentanoyloxy and the like,) carbamoyl, carbamoyloxy, cyano, morpholino, or methylsulfonylamino substituents and the like.
  • aryl when used alone means a homocyclic or polycyclic aromatic radical, whether or not fused, having the number of carbon atoms designated.
  • Preferred aryl groups include phenyl, napthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like (see e.g. Lang's Handbook of Chemistry (Dean, J. A., ed) 13th ed. (1985) Table 7-2).
  • substituted phenyl or “substituted aryl” denotes a phenyl group or aryl group substituted with one, two or three substituents chosen from halogen(F, Cl, Br, I), hydroxy, protected hydroxy, cyano, nitro, -C6 alkyl, Cj-C ⁇ alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, aminomethyl, protected aminomethyl, trifluoromethyl N-
  • substituted phenyl includes but are not limited to a mono- or di(halo)phenyl group such as 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl and the like; a mono- or di(hydroxy)phenyl group such as 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 3- or 4-nitrophenyl; a cyanophenyl group, for example, 4-cyanophenyl; a mono- or di(lower alkyl)phenyl group such as 4- methylphenyl, 2,4-di
  • substituted phenyl represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2- hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy-4-chlorophenyl and the like.
  • Preferred substituted phenyl groups include the 2- and 3-trifluoromethylphenyl, the 4-hydroxyphenyl, the 2-aminomethylphenyl and the 3-(N-(methylsulfonylamino))phenyl groups.
  • arylalkyl or “aralkyl” means one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl radical having the number of carbon atoms designated including but not limited to; benzyl, napthylmethyl, phenethyl, benzhydryl (diphenylmethyl), trityl, and the like.
  • a preferred arylalkyl group is the benzyl group.
  • substituted C ⁇ -Cioaryl-Ci-Cgalkyl denotes a Ci-Cgalkyl group substituted at any carbon with a C ⁇ -Cio-uyl group bonded to the alkyl group through any aryl ring position and substituted on the Ci-Cgalkyl portion with one, two or three groups chosen from halogen (F, Cl, Br, I), hydroxy, protected hydroxy, amino, protected amino, C ⁇ -C 7 acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carbamoyloxy, cyano, C ⁇ -C6alkylthio, N-(methylsulfonylamino) or C ⁇ -C4alkoxy.
  • halogen F, Cl, Br, I
  • hydroxy, protected hydroxy, amino, protected amino, C ⁇ -C 7 acyloxy nitro, carboxy, protected carboxy, carbamoyl, carbamoyloxy, cyano, C ⁇ -C6alkylthio,
  • the aryl group may be substituted with one, two, or three groups chosen from halogen, hydroxy, protected hydroxy, nitro, C ⁇ -C6alkyl, C ⁇ -C4alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, aminomethyl, protected aminomethyl, or an N- (methylsulfonylamino) group.
  • the substituents can be the same or different.
  • substituted C ⁇ -CioarylCi-Cgalkyl examples include groups such as 2-phenyl-l- chloroethyl, 2-(4-methoxyphenyl)ethyl, 2,6-dihydroxy-4-phenyl(n-hexyl), 5-cyano-3-methoxy-2-phenyl(n- pentyl), 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n- hexyl), 5-(4-aminomethyl phenyl)-3-(aminomethyl)(n-pentyl), and the like.
  • carboxy-protecting group refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound.
  • carboxylic acid protecting groups include 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6- trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'- dimethoxybenzhydryl, 2,2',4,4'-tetramethoxybenzhydryl, t-butyl, t-amyl, trityl,4-methoxytrityl, 4,4'- dimethoxytrityl, 4,4',4"-trimethoxytrityl, 2-phenylprop-2-yl, trimethylsilyl
  • protected carboxy refers to a carboxy group substituted with one of the above carboxy-protecting groups.
  • amide-protecting group refers to any group typically used in the peptide art for protecting the peptide nitrogens from undesirable side reactions.
  • Such groups include p- methoxyphenyl, 3,4-dimethoxybenzyl, benzyl, O-nitrobenzyl, di-(p-methoxyphenyl)methyl, triphenylmethyl, (p-methoxyphenyl)diphenylmethyl, diphenyl-4-pyridylmethyl, m-2-(picolyl)-N'-oxide, 5- dibenzosuberyl, trimethylsilyl, t-butyl dimethylsilyl, and the like. Further descriptions of these protecting groups can be found in "Protective Groups in Organic Synthesis", by Theodora W. Greene, 1981, John Wiley and Sons, New York.
  • heterocyclic group or “heterocyclic” or “HET” or “heterocyclyl” are used interchangeably herein and refer to any mono-, bi-, or tricyclic saturated, unsaturated, or aromatic ring having the number of atoms designated where at least one ring is a 5-, 6- or 7- membered ring containing from one to four heteroatoms selected from nitrogen, oxygen, and sulfur. Preferably at least one heteroatom is nitrogen (Lang's Handbook of Chemistry, supra).
  • the 5- membered ring has 0 to 2 double bonds and the 6- or 7-membered ring has 0 to 3 double bonds and the nitrogen or sulfur heteroatoms may optionally be oxidized, and any nitrogen heteroatom may optionally be quaternized.
  • the definition are any bicyclic groups where any of the above heterocyclic rings are fused to a benzene ring. Heterocyclics in which nitrogen is the heteroatom are preferred.
  • This invention provides novel prodrugs which are mono-, di-, or tri-halo-, preferably tri-halo- alkoxycarbonyl derivatives, such as trichloroalkoxycarbonyl derivatives of pharmaceutical agents, drugs or medicaments.
  • a pharmaceutical agent as described herein, is substituted according to, for example, the methods provided herein, to contain at least one novel prodrug moiety.
  • the halo-alkoxycarbonyl prodrug moieties of the present invention produce a derivative or prodrug of the parent compound which facilitates abso ⁇ tion by masking the ionic charge of the nitrogen containing functionality of the parent compound.
  • the prodrug moiety is sufficiently stable to survive premature cleavage in the stomach, intestines, and non-target sites.
  • the prodrug moiety is readily cleaved at the target site (e.g. the systemic circulation for most cardiovascular-based drugs) in a biologically relevant time frame and in high efficiency.
  • Suitable halo-alkoxycarbonyl prodrug moieties such as the trichloroalkoxycarbonyl moieties of the present invention produce by-products after metabolic cleavage of the prodrug moiety from the parent drug that are safe, non-toxic, and easily cleared by the system.
  • the by products are
  • the mechanism of prodrug cleavage does not have undesired detrimental biological repercussions (i.e. have an inhibitory effect on prodrug cleaving enzyme(s), etc.).
  • the prodrug moiety is easily and economically prepared.
  • halo-alkoxycarbonyl prodrug moiety is meant a compound of general formula:
  • [(H)o -2 (X) 1-3 ] is selected from the group consisting of X 3 , HX 2 , and H X and X is a halogen selected from the group consisting of F, Cl, Br, I or a combination thereof.
  • the halogen is flourine or chlorine or a combination thereof and more preferably the halogen is chlorine.
  • Preferred among the mono, di and tri-chloroalkoxycarbonyl groups are the trichloroalkoxycarbonyl groups.
  • halo-alkoxycarbonyl prodrug moieties of the present invention are straight chain or branched chain substituted or saturated aliphatic C 2 to C 6 alkyoxycarbonyl groups. Therefore in the foregoing formula, the subscript z is preferably 2-5.
  • Preferred among the branched and straight chain alkoxycarbonyl groups are the straight chain substituted or saturated aliphatic groups.
  • Preferred among the straight chain groups are the C 2 -C 6 substituted and saturated aliphatic groups and especially the saturated and substituted 2,2,2-trichloroethoxycarbonyl prodrug moieties.
  • the invention provides prodrugs moieties of the following structural formula: -COO(CR 2 R 3 )CCl 3
  • the prodrug moiety -COO(CR R )CC1 3 1) produces a neutrally charged prodrug derivative of the parent compound which increases permeability across lipophilic membranes, 2) can be easily and economically prepared from precursor alkyl chloroformates, 3) results in ethoxycarbonyl derivatives stable to pre-systemic cleavage and 4) the resulting by products of systemic cleavage are C0 2 and an alcohol. 2 3 2 3
  • the ethoxy group is -0(R R C)-, wherein R and R are the same or different and represent hydrogen, C ⁇ -C4alkoxy, C ⁇ -C4alkyl, cyano, and halo(F, Cl, Br, I)C ⁇ -C4alkyl, (ii) optionally substituted C ⁇ -Ci2alkyl, (iii) optionally substituted C3-C7alkenyl, (iv) optionally substituted C3-C 7 alkynyl,
  • 2,2,2-trichloroethoxycarbonyl moieties wherein the ethoxy group -OCR R -, R and R are the same or different and represent hydrogen, C ⁇ -C4alkoxy, C ⁇ -C4alkyl, cyano, and halo(F, Cl, Br, I)C ⁇ -C4alkyl.
  • R and R are methyl or H or a combination thereof. Preferred among these moieties is the -
  • the pharmaceutical agents are pharmaceutically active compounds comprising at least one polar or basic nitrogen-containing functionality Q.
  • Preferred pharmaceutical agents have an N-containing functionality, Q, having a pK a of the conjugate acid sufficiently high so that the molecules are at least 10% positively charged (associated with an H ion) at physiological pH.
  • Suitable parent pharmaceutical compounds comprise at least one Q group.
  • Q may be, for example (1) a primary, or secondary, amine or imine, (2) an amidino (aminoiminomethyl) group, (3) an aminoalkyleneamino group, (4) an iminoalkyleneamino group or (5) a guanidino group.
  • the parent compound contains at least one amino group including;
  • R is typically, but not limited to; (i) an optionally substituted radical selected from (a) -NR 7 R°*, (b) -
  • R , R , R , R , and R is independently selected from hydrogen, hydroxy, C]-C4alkoxy, C ⁇ -C4alkyl, cyano, and halo(F, Cl, Br, I)C ⁇ -C4alkyl, (ii) optionally substituted C 1 -Chalky 1, (iii) optionally substituted C3-C7alkenyl, (iv) optionally substituted C3-C 7 alkynyl, (v) optionally substituted C3-Ci2cycloalkyl, (vi) optionally substituted C5-Ci2cycloalkenyl, (vii) optionally substituted C ⁇ -C ⁇ aryl, (viii) optionally substituted C ⁇ -C6alkylC6-Ci4aryl, (ix) optionally substituted C3-C6alkenyl-C6-C ⁇ oaryl, (x) optionally substituted heterocyclyl, (xi) optionally substituted Ci-C ⁇ alkyl-
  • each R typically selected from (a) optionally substituted C ⁇ -C ⁇ aryloxy, (b) optionally substituted C6-Ci2arylamino, (c) optionally substituted 13 C6-Ci2aroyl, (d) optionally substituted C6-Ci2 rylthio, where the substituents are usually one to three R ,
  • each R typically selected from nitro, amino, Ci-Cgalkylamino, di-(C ⁇ -Cg)alkylamino, amidino, aminomethyleneimino, imino, imino-C ⁇ -C4alkyl, iminomethyleneamino, guanidino, C ⁇ -Cioarylamino, C]-
  • Ci-Cgalkyl Cg-alkyl, and Ci-Cgalkyl, (e) Ci-Cgalkoxy (f) Cj-Cgalkthio (g) halo(F, Cl, Br, I), (h) hydroxy, (i) mercapto, (j) Ci-Cgalkylcarbonyl, (k) carbamoyl, (1) formyl, (m) formyloxy, (n) carboxy, (o) carb-Cj-
  • Cg)dialkylcarboxamido (s) carbamoyloxy, (t) N-(C ⁇ -Cg)alkylcarbamoyloxy, (u) N-(C ⁇ -Cg),N-(C ⁇ - Cg)dialkylcarbamoyloxy, (v) Ci-Cgalkylsulfinyl, (w) Ci-Cg alkylsulfonyl, (x) Ci-Cgalkylsulfonato, (y) sulfo, (z) sulfonamido, (aa) N-(C ⁇ -Cg) alkylsulfonamido, (ab) N-(C ⁇ -Cg), N-(C ⁇ -Cg)dialkylsulfonamido, (ac) amino, (ad) Ci-Cg alkylamino, (ae) -Cg dialkylamino, (af) Cj-Cg acylamino, (a
  • R -R may independently be joined to form one or two optionally substituted heterocyclic rings, each ring optionally fused with one or two optionally substituted homocyclic or heterocyclic rings of from four to seven atoms where any heterocyclic ring contains from one to four heteroatoms selected from N, O, and S
  • any ring may be substituted with from one to three R , either isolated or conjugated with other nitrogen atoms to form groups including but not limited to aminomethyleneimino; (2) an amidino (aminoiminomethyl) group including;
  • R and R are the same or different and are as defined above for R ,
  • R and R are the same or different and are the same as R defined above,
  • guanidino (aminoiminomethyleneamino) group including;
  • R , R , and R are the same or different and are as defined above for R ,
  • the parent agent contains at least one amidino (aminoiminomethyl) group including;
  • R , R , and R are defined above, and guanidino groups including;
  • R , R , and R are defined above, and multiples thereof.
  • Exemplary preferred Q groups include the following:
  • Amidino groups such as B-Q wherein Q is;
  • Iminoalkyleneamino groups such as B-Q wherein Q is;
  • Preferred Q groups are the amidino groups and guanidino groups above and especially an B- amidino or B-guanidino wherein B is defined above.
  • B is preferably a substituted or unsubstituted phenyl, napthyl, or pyridyl.
  • Listed below are various representative parent pharmaceutical agents which can be used and which contain an appropriate polar or basic function. One skilled in the art will realize that the list below is not exclusive and the invention is applicable to other equivalent drugs, pharmaceuticals, or medicaments.
  • Butanoic acid 4-[[l-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(l-piperidinyl)ethyl]amino]-3-[[(4- methoxy-2,3,6-trimethylphenyl)sulfonyl] amino]-4-oxo-, [S-(R*,S*)]-
  • Glycinamide N-acetyl-4-(aminoiminomethyl)-D-phenylalanyl-L-2-cyclohexyl-N-[(l-methylpyridinium-4- yl)methyl]-, iodide
  • Glycinamide N-acetyl-4-(aminoiminomethyl)-L-phenylalanyl-N-[[4-(aminoiminomethyl)phenyl]methyl]-L- 2-cyclohexyl-
  • Glycinamide N-acetyl-4-(aminoiminomethyl)-L-phenylalanyl-L-2-cyclohexyl-N-[ 1 -( 1 -methylpyridinium-4- yl)ethyl]-, iodide,
  • Pentanamide 2-[[[4(aminoiminomethyl)phenyl]sulfonyl]amino]-N-[[(diphenylmethyl)amino]acetyl]-4- methyl-, (S)
  • Phenylalanine 3-(aminoiminomethyl)-N-[N-[(4-methylphenyl)sulfonyl]glycyl]-, methyl ester, Phenylalaninamide, l-[(phenylmethoxy)carbonyl]-L-prolyl-4-(aminoiminomethyl)-N-butyl-,
  • 2-Pyridinecarboxylic acid l-[3-[3-(aminoiminomethyl)phenyl]-l-oxo-2-[[(l,2,3,4-tetrahydro-2,5-dimethyl- 8-isoquinolinyl)sulfonyl]amino]propyl]-l,2,3,6-tetrahydro-4-methyl-, ethyl ester, [S-(R*,S*)]-
  • 3-Oxazolidineacetic acid 4-[[4-[[4-(aminoiminomethyl)phenyl]methoxy] phenyl]methyl]-2-oxo-, (S)- L-Tyrosinamide, N-[[4-(aminoiminomethyl)phenoxy]acetyl]glycyl-L-alpha.-aspartyl-0-methyl-,
  • drugs or pharmaceuticals containing an amidino functionality used for the treatment of cardiovascular disease. More preferred still are drugs or pharmaceuticals containing amidine functionality used as antithrombotics. Most preferred are drugs or pharmaceuticals containing amidine functionality that are glycoprotein Ilb/IIIa antagonists, Factor Xa, Factor Vila, trypsin or thrombin inhibitors.
  • the present invention relates to prodrugs of guanidine, thioguanidine or amidine containing compounds which are pharmaceutically active and, for example, are useful in inhibiting formation of thrombin, or in inhibiting platelet aggregation, or as fibrinogen receptor antagonists, and the like, such as those described in, for example:
  • Prefered prodrugs of the present invention include 2,2,2-trichloroethoxycarbonyl derivatives of the GPIIb/IIIa antagonists described in International Publication No. WO 93/08174 and U.S. Patent 5,565,449 the disclosures of which are specifically inco ⁇ orated herein by reference.
  • A-B is:
  • X is H and R is -CH 2 CCl 3 .
  • the compounds of this invention are meant to include those compounds wherein both a carboxylate and at least one appropriate Q group as described herein have been derivatized.
  • carboxyl groups are commonly derivatized by a hydroxyl group, an optionally substituted alkoxy, for example a lower (Cl-6) alkylamino or a N,N-dilower (Cl-4) alklyamino, or an optionally substituted alkoxy, for a example a lower (Cl-6) alkoxy whose alkyl moiety is optional substituted by hydroxy or an optionally substituted amino, for example amino, dimethyl amino, diethylamine, diethylamino, piperidino or mo ⁇ hilino) halogen, a lower (Cl-6)alkoxy, a lower(Cl-6)alkythio or an optionally substituted dioxolenyl (for example 5-methyl 2 oxo 1,3-dioxolenyl or a group represented by the formula of -OCHROCOR (EP 0529 858 Al)).
  • an optionally substituted alkoxy for example a lower (Cl-6)
  • the compounds of this invention can be produced by, for example, the methods described herein below.
  • these functional groups may, when necessary, be protected with a protective group conventionally used in the field of organic synthesis.
  • a protective group conventionally used in the field of organic synthesis.
  • Introduction and elimination of protecting groups may be conducted in accordance with conventional practice.
  • the formation reaction may require the protection of the carboxy groups using one of, for example, the exter derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups.
  • Carboxy-protecting groups are known in the art.
  • the formation reactions may also require the protection of, for example, primary and secondary amines which may be affected by the use of a protective group such as tert-butoxycarbonyl, benxyloxycarbonyl, p-nitrobenzyloxy carbonyl and triphenylmethyl or the like.
  • a protective group such as tert-butoxycarbonyl, benxyloxycarbonyl, p-nitrobenzyloxy carbonyl and triphenylmethyl or the like.
  • the compounds of the present invention can be prepared by conventional methods.
  • An exemplary method for producing the prodrugs of the instant invention can be depicted as follows:
  • the first step of the method for preparing the prodrugs of the present invention consists of reacting a parent drug or pharmaceutical agent as described above with an alkyl formate compound of formula II where Y represents a halogen such as chlorine or an amino conjugate such as a pyrimidinium ion or a good leaving group such as a substituted phenoxy as, for example p-nitrophenoxy, dinitrophenoxy, flourophenoxy or diflourophenoxy.
  • Y represents a halogen such as chlorine or an amino conjugate such as a pyrimidinium ion or a good leaving group such as a substituted phenoxy as, for example p-nitrophenoxy, dinitrophenoxy, flourophenoxy or diflourophenoxy.
  • the reaction is carried out in solvents such as dichloromethane, dichloroethane, tetrahydrofuran, dioxane, diethyl ether, dimethoxyethane and the like or other solvents such as ethylacetate or acetonitrile.
  • solvents such as dichloromethane, dichloroethane, tetrahydrofuran, dioxane, diethyl ether, dimethoxyethane and the like or other solvents such as ethylacetate or acetonitrile.
  • the reaction can be carried out at temperatures from -78 C to 50 C but preferably carried out at 1 C to room temperature.
  • exemplary schmatic R refers to the halo-alkyl group.
  • the reaction is carried out in the presence of a base such as potassium bicarbonate, pyridine, triethylamine, 1,8- bis(dimethyl amino), napthalene, N-methylmo ⁇ holine and the
  • prodrugs of the instant invention can be used in a manner analogous to the parent compound.
  • the prodrug when the ⁇ ⁇ ** group is a thrombin inhibitor, the prodrug will be useful as a thrombin inhibitor in dosages and dosage forms as described for the particular thrombin inhibitor. If the Atj ⁇ group is an inhibitor of platelet aggregation, the prodrug will be useful as an inhibitor of platelet aggregation in dosages and dosage forms as described for the inhibitor of platelet aggregation.
  • the specific dose of a compound administered according to this invention to obtain a therapeutic or prophylactic effect will, of course, be determined by the particular parent pharmaceutical agent and further by the particular circumstances surrounding the administration, including, for example, the condition being treated. Typical daily doses of the compounds are between about 0.01 mg/kg and about 100 mg/kg. The dose regime will understandably vary. For example, several above noted parent agents may be administered prophylactically as a single daily dose or in multiple doses such as between 2 and 5 times per day as appropriate.
  • the compounds of the present invention may be serine protease inhibitors and in particular may inhibit thrombin, Factor Xa, Factor Vila and or trypsin.
  • Such compounds are useful for the treatment and prevention of those particular processes which involve the production and/or action of thrombin.
  • the uses include but are not limited to the treatment and prevention of peripheral arterial obstruction, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, dissecting aneurysm, transient ischemic attack, restenosis, stroke and other occlusive disease or disorders such as unstable angina, disseminated intravascular coagulation, sepsis, surgical or infective shock, postoperative and post-delivery trauma, angioplasty, cardiopulmonary bypass and coronary bypass, incompatible blood transfusion, amotio placentae, thrombotic thrombocytopenic pu ⁇ ura, asthma, chronic or acute renal disease, diabetes, inflammations, atherosclerosis, hemolytic uremic syndrome, symmetric peripheral necrosis, and allograft rejection in mammals including human.
  • Such A ⁇ ⁇ compounds and hence the prodrugs of the instant invention can be used for enhancing the action of a thrombolytic agent and for preventing reobstruction after percutaneous transluminal coronary recanalization, preventing reobstruction after percutaneous transluminal coronary angioplasty and preventing thrombocytopenia due to dialysis, for example.
  • the glycoprotein Ilb/IIIa appears on the surface of platelets as a noncovalent heterodimeric complex and has been shown to interact with, fibronectin, vitronectin, von Willebrand factor, and thrombospondin.
  • Arg-Gly-Asp RGD sequences which serve as a basic recognition feature for binding GPIIb/IIIa and certain other integrins.
  • RGD Arg-Gly-Asp
  • small peptides containing the RGD fragment have been shown to successfully compete with larger proteins (see references, supra).
  • the interaction between the particular receptor and GPIIbllla is the common ultimate event in the aggregation cascade regardless of the mechanism of platelet activation.
  • Arg-Gly-Asp-based antagonists of the platelet GPIIbllla /receptor interaction act as a stimulus-independent inhibitor of platelet aggregation (International Publication No. WO 95/04057). Therefore the compounds and hence the prodrugs of the instant invention can be used to prevent the development of blood platelet thrombosis and can be used in the treatment and prevention of diseases and disorders involving inappropriate or non- beneficial platelet aggregation or thrombosis.
  • the prodrugs of the instant invention can be administered topically, orally or parenterally such as subcutaneously, intravenously, as well as by nasal, rectal or sublingual application to various mammalian species including human.
  • the pharmaceutical composition containing the prodrug of the instant invention may be in a unit form suitable for oral use, for example, as tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such composition may contain one or more agents, such as those selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically palatable preparations.
  • agents such as those selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically palatable preparations.
  • Formulations for oral use include tablets which contain the prodrug in admixture with a non-toxic pharmaceutically acceptable excipients.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium chloride lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents for example maize starch, gelatin or acacia and lubricating agents for example magnesium stearate, stearic acid or talc.
  • the tablets may be coated by known techniques to delay disintegration and abso ⁇ tion in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glycerol monostearate or glycerly distearate may be employed.
  • Formulation for oral use may also be presented as hard gelatin capsules wherein the prodrug is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions usually contain the prodrug in admixture with appropriate excipients.
  • excipients are suspending agents, for example sodium carboxymethycellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, dispersing or wetting agents which may be a naturally-occurring phosphatide, for example, lecithin; a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol for example heptadecaethyleneoxycetanol; a condensation product of ethylene oxide with a partial ester derived from fatty acids and a hexitol such as polyoxyethlene sorbitol monooleate or a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example,
  • the aqueous suspension may also contain one or more preservatives, for example, ethyl, n-propyl, or a p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
  • preservatives for example, ethyl, n-propyl, or a p-hydroxybenzoate
  • coloring agents for example, ethyl, n-propyl, or a p-hydroxybenzoate
  • flavoring agents for example, ethyl, n-propyl, or a p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the prodrug in a vegetable oil, for example, arachis oil, olive oil, sesame oil, peanut oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified above. Additional excipients may also be present.
  • the prodrugs may also be administered in the form of suppositories.
  • These compositions can be prepared by mixing the prodrug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug, for example cocoa butter and polyethylene glycols.
  • GPIIb/IIIa binding epitope on fibrinogen consisting of the sequence Arg-Gly-Asp (RGD) has been identified and a number of synthetic peptides containing this sequence have been shown to be GPIIb/IIIa antagonists (see, Detailed Description of the Preferred Embodiments). Based upon the structural features of this RGD epitope, potent nonpeptidal antagonists of the general structure I have been prepared.
  • IC50 are measured as ADP induced aggregation in citrated plasma.
  • EXAMPLE 2 The preparation of mono and and double prodrugs of these materials which masked the ionic charges were prepared and tested for oral bioavailability.
  • Mouse ID50 were calculated from mice dosed at 100 mg/kg orally and sacrificed at either 1 or 3 hours timepoints, exsanguinated and ex vivo platelet aggregation measured to determine ID50.
  • Example 7 4H-l,4-Benzodiazepine-4-propanoic acid, 6-chloro-7-[[4-(N-2,2,2- trichloroethoxycarbonyiaminoiminomethyl)benzoyl]amino]-l,2,3,5-tetrahydro-l-methyl-2,5-dioxo-, sec-butyl ester,
  • Example 8 4H-l,4-Benzodiazepine-4-propanoic acid, 6-chloro-7-[[4-(N-2,2,2- trichloroethoxycarbonylaminoiminomethyl)benzoyl]amino]-l,2,3,5-tetrahydro-.alpha.,l-dimethyl-2,5- dioxo- , ethyl ester:
  • the electronically activated alkoxycarbonyl amidines e.g trichloroethoxy, phenoxy
  • the acyloxyalkoxy derivatives showed very good conversion (>10X) in comparison to the ethoxycarbonyl derivative.
  • the acetoxyethoxy derivative almost complete conversion to the parent was observed within 30 minutes.
  • the thioethoxycarbonyl derivative was superior to the simple ethoxycarbonyl derivative, this prodrug was poorer than most of the other derivatives.
  • Similar plasma stability experiments with human plasma were consistent with the above results but absolute values were smaller, due in part to the lower levels of hydrolytic enzymes present in human plasma.
  • the acyloxyethoxy derivative showed quantitative conversion to the parent within 6 hours.
  • the phenoxycarbonyl derivative was quantitatively converted to the parent.
  • the trichloro ethoxy derivative was greater than 8 times more labile than the ethoxy derivatve.
  • the double prodrugs where the amidine functionality is masked as a physiologically labile alkoxycarbonyl amidine were screened in a mouse assay to determine their oral bioavailability.
  • mice Oral bioavailability was assessed by dosing mice at 100 mg/kg orally and sacrificing the mice at either 1 or 3 hour timepoints. The mice were exsanguinated and ex vivo platelet aggregation measured by ID 50 . Results
  • Oral bioavailability was assessed by dosing dogs or rats at various concentrations orally and assessing the oral bioavailability at either 1 or 3 hour timepoints.
  • the trichloroethoxy derivatives had the most profound effect on improving the oral bioavailability in the rats. While the acyloxyalkoxycarbonyl and the phenoxy carbonyl compounds had shown good conversion to the corresponding parent in plasma and i.v. prodrug experiments, they did not show good oral bioavailability in rats. It could be that these prodrugs are too labile and are prematurely hydrolyzed in the stomach or intestines prior to transport. It was only the frichloroethoxycarbonyl prodrugs that showed enhanced oral bioavailability in the rat.
  • the frichloroethoxycarbonyl prodrugs provided a dramatic increase in oral bioavailability relative to their ethoxycarbonyl analogs.
  • Figure 6 graphically depicts bioavailability of various prodrugs in dogs after oral administration.
  • Use of the 2,2,2-trichloroethoxycarbonyl prodrug moiety doubled the oral bioavailability of compounds of the general structure (I) relative to the ethoxycarbonyl derivative when administereed orally at comparable doses to dogs. At lower doses the oral bioavailability increased to 29%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

On décrit des dérivés haloalcoxycarbonyles en tant que fractions de promédicaments pour des agents pharmaceutiques contenant une valence fonctionnelle élémentaire ou à base d'azote polaire. Lesdits promédicaments sont utilisés comme compositions pharmaceutiques ou dans des méthodes de traitement.
PCT/US1998/007092 1997-04-15 1998-04-08 Promedicaments haloalcoxycarbonyles WO1998046576A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69830577T DE69830577T2 (de) 1997-04-15 1998-04-08 Halo-alkoxycarbonylverbindungen
EP98913417A EP0975608B1 (fr) 1997-04-15 1998-04-08 Promedicaments haloalcoxycarbonyles
AU67972/98A AU6797298A (en) 1997-04-15 1998-04-08 Halo-alkoxycarbonyl prodrugs
AT98913417T ATE297904T1 (de) 1997-04-15 1998-04-08 Halo-alkoxycarbonylverbindungen
JP54404298A JP2001521522A (ja) 1997-04-15 1998-04-08 新規なハロ−アルコキシカルボニルプロドラッグ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84336997A 1997-04-15 1997-04-15
US08/843,369 1997-04-15

Publications (2)

Publication Number Publication Date
WO1998046576A2 true WO1998046576A2 (fr) 1998-10-22
WO1998046576A3 WO1998046576A3 (fr) 1999-01-28

Family

ID=25289769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007092 WO1998046576A2 (fr) 1997-04-15 1998-04-08 Promedicaments haloalcoxycarbonyles

Country Status (6)

Country Link
EP (1) EP0975608B1 (fr)
JP (1) JP2001521522A (fr)
AT (1) ATE297904T1 (fr)
AU (1) AU6797298A (fr)
DE (1) DE69830577T2 (fr)
WO (1) WO1998046576A2 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004103A1 (fr) * 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones et quinazolines
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
WO2004046148A1 (fr) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives de xanthine, leur production et leur utilisation en tant que medicaments
WO2005097798A1 (fr) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
WO2006000354A1 (fr) 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh Nouveaux imidazoles et triazoles, procede pour les produire et leur utilisation en tant que medicaments
US7015323B2 (en) 2003-05-20 2006-03-21 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
WO2006029769A1 (fr) 2004-09-14 2006-03-23 Boehringer Ingelheim International Gmbh Nouvelles 3-methyl-7-butinyl-xanthines, leur production et leur utilisation comme medicaments
WO2006078283A2 (fr) 2004-04-30 2006-07-27 Genentech, Inc. Inhibiteurs de quinoxaline de la voie de signalisation hedgehog
EP1953162A1 (fr) 2001-02-24 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Dérivé de xanthine, sa fabrication et son utilisation en tant que médicament
US7425641B2 (en) 1999-08-07 2008-09-16 Boehringer Ingelheim Pharma Kg Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
EP2058311A2 (fr) 2002-08-21 2009-05-13 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que médicament
WO2009126863A2 (fr) 2008-04-11 2009-10-15 Genentech, Inc. Inhibiteurs pyridiles de signalisation hedgehog
WO2011072064A1 (fr) 2009-12-08 2011-06-16 Array Biopharma Inc. Spiro[chromane-4,4'-imidazol]ones en tant qu'inhibiteurs de bêta-sécrétase
WO2011123674A1 (fr) 2010-03-31 2011-10-06 Array Biopharma Inc. Composés pour traiter des maladies neurodégénératives
WO2011130741A1 (fr) 2010-04-16 2011-10-20 Array Biopharma Inc. Composés pour le traitement de maladies neurodégénératives
EP3133073A2 (fr) 2012-01-03 2017-02-22 Curis, Inc. Inhibiteurs d'iap
WO2018045071A1 (fr) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires
WO2022115521A1 (fr) 2020-11-25 2022-06-02 Servier Pharmaceuticals, Llc Dérivés de pyrrolo-, pyrazolo- et triazolopyridazine substitués par (hétéro)aryle en tant qu'inhibiteurs de mat2a

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008174A1 (fr) * 1991-10-18 1993-04-29 Genentech, Inc. INHIBITEURS NON PEPTIDYLES A BASE D'INTEGRINE SPECIFIQUES DU RECEPTEUR GPIIbIII¿a?

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008174A1 (fr) * 1991-10-18 1993-04-29 Genentech, Inc. INHIBITEURS NON PEPTIDYLES A BASE D'INTEGRINE SPECIFIQUES DU RECEPTEUR GPIIbIII¿a?

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCDOWELL ET AL: "From Peptide to Non-peptide." J.AMER.CHEM.SOC., vol. 116, no. 12, 1994, pages 5077-5083, XP002069808 *
RUBAS W ET AL: "The effect of chemical modifications on octanol/water partition (log D) and permeabilities across Caco-2 monolayers" ADV. DRUG DELIVERY REV. (ADDREP,0169409X);97; VOL.23 (1-3); PP.157-162, 15 January 1997, GENENTECH, INC., DEPARTMENT OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT, 460 POINT SAN BRUNO BOULEVARD;SOUTH SAN FRANCISCO; 94080-4990; CA; USA (US), XP002069807 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US7071173B2 (en) 1998-02-13 2006-07-04 Medivir Ab Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine
US6974802B2 (en) 1998-02-13 2005-12-13 Medivir Ab Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine
US7825238B2 (en) 1998-02-13 2010-11-02 Medivir Ab Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine
US6506744B1 (en) 1999-07-13 2003-01-14 Hoffmann-La Roche Inc. Benzazepinone-derivatives
WO2001004103A1 (fr) * 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones et quinazolines
US7425641B2 (en) 1999-08-07 2008-09-16 Boehringer Ingelheim Pharma Kg Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
EP2298769A1 (fr) 2001-02-24 2011-03-23 Boehringer Ingelheim Pharma GmbH & Co. KG Dérivé de xanthine, sa fabrication et son utilisation en tant que médicament
EP1953162A1 (fr) 2001-02-24 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Dérivé de xanthine, sa fabrication et son utilisation en tant que médicament
EP2070539A1 (fr) 2002-08-21 2009-06-17 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que médicament
EP2060573A2 (fr) 2002-08-21 2009-05-20 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que médicament
EP2058311A2 (fr) 2002-08-21 2009-05-13 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que médicament
WO2004046148A1 (fr) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives de xanthine, leur production et leur utilisation en tant que medicaments
US7015323B2 (en) 2003-05-20 2006-03-21 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
US7166600B2 (en) 2003-05-20 2007-01-23 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
WO2005097798A1 (fr) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
WO2006078283A2 (fr) 2004-04-30 2006-07-27 Genentech, Inc. Inhibiteurs de quinoxaline de la voie de signalisation hedgehog
WO2006000354A1 (fr) 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh Nouveaux imidazoles et triazoles, procede pour les produire et leur utilisation en tant que medicaments
WO2006029769A1 (fr) 2004-09-14 2006-03-23 Boehringer Ingelheim International Gmbh Nouvelles 3-methyl-7-butinyl-xanthines, leur production et leur utilisation comme medicaments
WO2009126863A2 (fr) 2008-04-11 2009-10-15 Genentech, Inc. Inhibiteurs pyridiles de signalisation hedgehog
WO2011072064A1 (fr) 2009-12-08 2011-06-16 Array Biopharma Inc. Spiro[chromane-4,4'-imidazol]ones en tant qu'inhibiteurs de bêta-sécrétase
WO2011123674A1 (fr) 2010-03-31 2011-10-06 Array Biopharma Inc. Composés pour traiter des maladies neurodégénératives
WO2011130741A1 (fr) 2010-04-16 2011-10-20 Array Biopharma Inc. Composés pour le traitement de maladies neurodégénératives
EP3133073A2 (fr) 2012-01-03 2017-02-22 Curis, Inc. Inhibiteurs d'iap
US11096982B2 (en) 2012-01-03 2021-08-24 Genentech, Inc. Inhibitors of IAP
US11963994B2 (en) 2012-01-03 2024-04-23 Genentech, Inc. Inhibitors of IAP
WO2018045071A1 (fr) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires
USRE49934E1 (en) 2016-08-31 2024-04-23 Servier Pharmaceuticals Llc Inhibitors of cellular metabolic processes
WO2022115521A1 (fr) 2020-11-25 2022-06-02 Servier Pharmaceuticals, Llc Dérivés de pyrrolo-, pyrazolo- et triazolopyridazine substitués par (hétéro)aryle en tant qu'inhibiteurs de mat2a

Also Published As

Publication number Publication date
ATE297904T1 (de) 2005-07-15
AU6797298A (en) 1998-11-11
WO1998046576A3 (fr) 1999-01-28
EP0975608A2 (fr) 2000-02-02
DE69830577D1 (de) 2005-07-21
DE69830577T2 (de) 2006-05-04
JP2001521522A (ja) 2001-11-06
EP0975608B1 (fr) 2005-06-15

Similar Documents

Publication Publication Date Title
EP0975608B1 (fr) Promedicaments haloalcoxycarbonyles
AU689762B2 (en) Bicyclic fibrinogen antagonists
US5403836A (en) Benzazepine platelet aggregation inhibitors having specificity for the GPIIb IIIa receptor
USH725H (en) Ureido amino and imino acids, compositions and methods for use
EP1326849B1 (fr) Derives de la benzodiazepine utilises comme inhibiteurs de la gamma-secretase
US5565449A (en) Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
SK281532B6 (sk) Použitie benzodiazepínov, benzodiazepínové deriváty a farmaceutický prostriedok s ich obsahom
HUT76282A (en) Benzazepine and benzodiazepine derivatives, pharmaceutical compositions containing them, process for producing them and their use
EP0702671A1 (fr) Antagonistes bicycliques du fibrinogene
US6037343A (en) Fibrinogen receptor antagonists
EP1673347B1 (fr) Derives de dibenzo-azepine et de benzo-diazepine utilises en tant qu'inhibiteurs de la gamma-secretase
US5716951A (en) Tricyclic inhibitors of the vitronectin receptor
AU672390B2 (en) Benzodiazepin derivatives useful as CCK-receptor antagonists
CA1276146C (fr) Composes de type 1,5-benzodiazepine
AU703665B2 (en) Novel N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3 yl)-3-amides
US5900422A (en) Fibrinogen receptor antagonists
US7109326B2 (en) Halo-alkoxycarbonyl prodrugs
US20010020019A1 (en) Novel halo-alkoxycarbonyl prodrugs
US6403578B1 (en) Bicyclic fibrinogen antagonists
US4692455A (en) Certain acyclic, alicyclic, aromatic or heterocyclic derivatives of 3-benzoylamino-2-oxo- butyl-amino-carbonyl-oxy-3-propanoic acids, esters thereof, pharmaceutical compositions containing same and their enkephalinase inhibiting properties
US5756519A (en) Fibrinogen receptor antagonists
US4636522A (en) Acylaminoalkanoyl urethanes or thiourethanes
PL173030B1 (pl) Nowe sulfonamidokarboksamidy i sposób ich wytwarzania
AU4380301A (en) Bicyclic fibrinogen antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998913417

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 544042

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998913417

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1998913417

Country of ref document: EP